Aliases & Classifications for Spondylitis

MalaCards integrated aliases for Spondylitis:

Name: Spondylitis 12 74 54 43 15 71

Classifications:



External Ids:

Disease Ontology 12 DOID:6590
ICD9CM 34 720.8 720.89
MeSH 43 D013166
ICD10 32 M46
UMLS 71 C0029644 C0038012

Summaries for Spondylitis

MalaCards based summary : Spondylitis is related to juvenile ankylosing spondylitis and fibromyalgia, and has symptoms including sciatica An important gene associated with Spondylitis is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Loxoprofen and Aceclofenac have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Spondylitis is an inflammation of the vertebra. It is a form of spondylopathy. In many cases,... more...

Related Diseases for Spondylitis

Diseases related to Spondylitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1069)
# Related Disease Score Top Affiliating Genes
1 juvenile ankylosing spondylitis 34.4 TNFRSF1B TNF IL1RN ERAP1
2 fibromyalgia 32.9 TNF IL6 CRP
3 spondyloarthropathy 1 31.8 TNFRSF1B TNF TAP2 NOD2 IL23R IL1RN
4 spondylarthropathy 31.1 TNF NOD2 LTA
5 synovitis 31.1 TNF IL6 IL1RN CRP
6 amyloidosis 31.1 TNF IL6 IL1RN CRP
7 juvenile rheumatoid arthritis 31.1 TNFRSF1B TNF LTA IL6 IL1RN CRP
8 spondyloarthropathy 30.9 TNF LTA IL6 IL17A HLA-C HLA-B
9 osteomyelitis 30.8 TNF NOD2 IL6 IL1RN
10 bursitis 30.8 TNFRSF1B TNF CRP
11 iridocyclitis 30.8 TNFRSF1B TNF IL6 IL17A HLA-B CRP
12 conjunctivitis 30.7 TNF IL6 HLA-B
13 urethritis 30.7 TNF IL6 CRP
14 pulmonary tuberculosis 30.7 TNF IL6 IL17A CRP
15 myositis 30.6 TNF IL6 IL17A HLA-B
16 arthropathy 30.6 TNF MICA LTA IL6 IL1RN HLA-B
17 interstitial lung disease 30.5 TNF IL6 IL17A CRP
18 fasciitis 30.5 TNF IL6 IL1RN
19 chlamydia 30.5 TNF IL6 IL17A CRP
20 osteoarthritis 30.5 TNF IL6 IL1RN IL17A CRP
21 ankylosis 30.5 TNFRSF1B TNF ERAP1 CRP CCR6
22 brucellosis 30.5 TNF MICA IL6 IL1RN IL17A CRP
23 sleep disorder 30.5 TNF IL6 CRP
24 relapsing polychondritis 30.4 IL6 IL17A CRP
25 purpura 30.4 TNF IL6 CRP
26 uveitis 30.4 TNFRSF1B TNF NOD2 LTA IL6 IL17A
27 end stage renal failure 30.4 TNF IL6 IL1RN CRP
28 miliary tuberculosis 30.3 TNFRSF1B TNF CRP
29 systemic autoimmune disease 30.3 IL6 IL17A CRP
30 pericarditis 30.3 TNF IL6 IL1RN CRP
31 tendinitis 30.3 TNFRSF1B TNF IL6 CRP
32 macular retinal edema 30.3 TNFRSF1B TNF IL6
33 enthesopathy 30.3 TNFRSF1B TNF ERAP1 CRP CCR6
34 extrapulmonary tuberculosis 30.3 TNF IL1RN CRP
35 transverse myelitis 30.3 TNF IL6 IL17A
36 meningitis 30.3 TNF IL6 IL17A HLA-B CRP
37 duodenal ulcer 30.2 TNF LTA IL6 IL1RN
38 vasculitis 30.2 TNFRSF1B TNF IL6 IL17A HLA-B CRP
39 periodontitis 30.2 TNF IL6 IL1RN IL17A CRP
40 apnea, obstructive sleep 30.2 TNF IL6 CRP
41 systemic onset juvenile idiopathic arthritis 30.2 TNF IL1RN
42 retinal vascular disease 30.2 TNF IL6 CRP
43 toxoplasmosis 30.2 TNF NOD2 IL6
44 tonsillitis 30.2 TNF LTA IL6
45 endocarditis 30.2 TNFRSF1B TNF IL6 IL17A CRP
46 pleurisy 30.1 TNF IL1RN CRP
47 placenta disease 30.1 TNF IL6 CRP
48 pyelonephritis 30.1 TNF IL6 CRP
49 ileus 30.1 TNF IL6 IL17A CRP
50 sleep apnea 30.1 TNF IL6 CRP

Comorbidity relations with Spondylitis via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Spondylitis:



Diseases related to Spondylitis

Symptoms & Phenotypes for Spondylitis

UMLS symptoms related to Spondylitis:


sciatica

GenomeRNAi Phenotypes related to Spondylitis according to GeneCards Suite gene sharing:

26 (show all 25)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.87 HLA-B HLA-C
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.87 HLA-B HLA-C
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.87 HLA-B HLA-C
4 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.87 MICA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.87 HLA-C
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.87 HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.87 HLA-C
8 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.87 NOD2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.87 NOD2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.87 HLA-B HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.87 HLA-B HLA-C MICA NOD2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.87 NOD2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.87 HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.87 NOD2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.87 HLA-B HLA-C
16 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.87 NOD2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.87 NOD2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.87 MICA
19 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.87 HLA-C
20 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.87 MICA
21 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.87 HLA-B HLA-C
22 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.87 HLA-B HLA-C
23 Increased shRNA abundance (Z-score > 2) GR00366-A-77 9.87 NOD2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.87 MICA
25 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.87 HLA-C

MGI Mouse Phenotypes related to Spondylitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.93 CCR6 ERAP1 IL17A IL1RN IL23R IL6
2 immune system MP:0005387 9.77 CCR6 CRP ERAP1 IL17A IL1RN IL23R
3 skeleton MP:0005390 9.32 DKK1 IL17A IL1RN IL6 LTA NOD2

Drugs & Therapeutics for Spondylitis

Drugs for Spondylitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Loxoprofen Approved Phase 4 80382-23-6, 68767-14-6 3965
2
Aceclofenac Approved, Investigational Phase 4 89796-99-6
3
Pamidronate Approved Phase 4 40391-99-9 4674
4
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
5
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
6
carbamide peroxide Approved Phase 4 124-43-6
7
Tofacitinib Approved, Investigational Phase 4 477600-75-2
8
Sulfasalazine Approved Phase 4 599-79-1 5353980 5359476
9
Hydroxychloroquine Approved Phase 4 118-42-3 3652
10
Etanercept Approved, Investigational Phase 4 185243-69-0
11
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
12
Acetaminophen Approved Phase 4 103-90-2 1983
13
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
14 Anti-Infective Agents Phase 4
15 Natriuretic Agents Phase 4
16 Natriuretic Peptide, Brain Phase 4
17 Tripterygium Phase 4
18 Mitogens Phase 4
19 Endothelial Growth Factors Phase 4
20 Cholestyramine Resin Phase 4
21 Tocolytic Agents Phase 4
22 Cyclooxygenase 2 Inhibitors Phase 4
23 Protein Kinase Inhibitors Phase 4
24 Antibodies, Monoclonal Phase 4
25 Antibodies Phase 4
26 Immunoglobulins Phase 4
27 Antimalarials Phase 4
28 Antiparasitic Agents Phase 4
29 Antiprotozoal Agents Phase 4
30 Analgesics, Non-Narcotic Phase 4
31 Anti-Inflammatory Agents, Non-Steroidal Phase 4
32 Analgesics Phase 4
33 Cyclooxygenase Inhibitors Phase 4
34 Antipyretics Phase 4
35 Narcotics Phase 4
36 Central Nervous System Depressants Phase 4
37 Analgesics, Opioid Phase 4
38
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
39
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
40
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
41 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
42
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
43
rituximab Approved Phase 2, Phase 3 174722-31-7 10201696
44
Certolizumab pegol Approved Phase 3 428863-50-7
45
Etoricoxib Approved, Investigational Phase 3 202409-33-4 123619
46
Misoprostol Approved Phase 3 59122-46-2 5282381
47
Apremilast Approved, Investigational Phase 3 608141-41-9 11561674
48
Esomeprazole Approved, Investigational Phase 3 161973-10-0, 161796-78-7, 119141-88-7 4594 9568614
49
Upadacitinib Approved, Investigational Phase 3 1310726-60-3
50 Brodalumab Approved, Investigational Phase 3 1174395-19-7

Interventional clinical trials:

(show top 50) (show all 414)
# Name Status NCT ID Phase Drugs
1 Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry Unknown status NCT02492217 Phase 4 Adalimumab
2 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
3 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
4 Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
5 Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
6 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
7 A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
8 The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
9 Multicentre, Open-Labeled Study Of Etanercept In The Treatment Of Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
10 An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
11 A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
12 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
13 An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)
14 A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis Completed NCT00247962 Phase 4 etanercept;sulphasalazine (SSZ)
15 Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls Completed NCT00778869 Phase 4
16 Effect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
17 Effect of Anti-TNF(Alpha)Treatment on Circulating Endothelial Progenitor Cells (EPCs) and Vascular Stiffness in AS Completed NCT01212653 Phase 4 Simponi
18 Sequential Application of Yisaipu® and Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Treating Mild-to-Moderate Ankylosing Spondylitis: the Mid-term Follow-up Result Completed NCT03411798 Phase 4 Yisaipu®
19 A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams
20 A Clinical Trial About the Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis: a 12-week, Multi-center, Randomized, Double-blind, Active Drug and Placebo Compared Clinical Trial Completed NCT00953979 Phase 4 kunxian capsule
21 An Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
22 A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
23 Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study Completed NCT00779935 Phase 4
24 Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis Completed NCT00779012 Phase 4
25 Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy Completed NCT01517620 Phase 4 Total Glucosides Paeony Capsules
26 Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis: a Prospective, Randomized Multicentric Study on Disease Activity Guided Etanercept Tapering or Discontinuation Completed NCT03880968 Phase 4 tapering or discontinuation of etanercept
27 Efficacy and Safety of Loxoprofen Hydrogel Patch Versus Loxoprofen Tablet in Patients With Ankylosing Spondylitis: a 4-week Randomized, Open-label Study Completed NCT03800797 Phase 4 Loxoprofen sodium hydrogel patch;Loxoprofen sodium tablet
28 A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJECTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WHO ACHIEVED ADEQUATE 24 WEEK RESPONSE Completed NCT02509026 Phase 4
29 A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Completed NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex
30 The Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging Correlation Completed NCT00432432 Phase 4 Infliximab and MTX
31 Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012 Completed NCT01668004 Phase 4
32 Chung Shan Medical University Hospital, Taiwan Completed NCT00647517 Phase 4 Ultracet
33 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
34 Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial Completed NCT01718951 Phase 4 golimumab;Pamidronate
35 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the NSAID-sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM) Completed NCT02763046 Phase 4 AIN457/Secukinumab Placebo; Biological: AIN457/Secukinumab
36 Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial Completed NCT00715091 Phase 4 diclophenac;diclophenac
37 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Three Years' Following-up Study Completed NCT02915354 Phase 4 Etanercept
38 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
39 Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Results From MRI Finding Completed NCT03190603 Phase 4 Celecoxib
40 Evaluation of Clinical Value of Standardized Protocol for Dose-reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy: Open-label, Controlled, Randomized, Multicenter Trial. Completed NCT01604629 Phase 4 Reduced doses of anti-TNF;Stable doses of anti-TNF
41 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
42 Treatment of Active Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection: a Randomized, Double-blind, Multicentral Clinical Trial to Investigate the Efficacy and Safety of Yisaipu® Completed NCT02364479 Phase 4 50mg Yisaipu;25mg etanercept;Placebo
43 A Multicenter,Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis Recruiting NCT03932006 Phase 4 Fengshigutong Capsule plus Imrecoxib;Fengshigutong Capsule;Imrecoxib
44 A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap) Recruiting NCT03350815 Phase 4 150 mg open-label secukinumab;150 mg double-blinded secukinumab;300 mg double-blinded secukinumab
45 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Recruiting NCT03733925 Phase 4 Golimumab
46 Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study Recruiting NCT03473665 Phase 4 Indomethacin;Diclofenac;Meloxicam;Celecoxib
47 TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study) Recruiting NCT03639740 Phase 4 Secukinumab 150 milligram [Cosentyx]
48 GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC). Recruiting NCT02687724 Phase 4 Golimumab (GLM)
49 COmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre Trial Active, not recruiting NCT02758782 Phase 4 Celecoxib
50 Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study Not yet recruiting NCT04077957 Phase 4 Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept (50mg per week, for 4 weeks);Etanercept (50mg per week, for 2 weeks);Etanercept (50mg per week)

Search NIH Clinical Center for Spondylitis

Cochrane evidence based reviews: spondylitis

Genetic Tests for Spondylitis

Anatomical Context for Spondylitis

MalaCards organs/tissues related to Spondylitis:

40
Bone, T Cells, Testes, Spinal Cord, Lung, Endothelial, Heart

Publications for Spondylitis

Articles related to Spondylitis:

(show top 50) (show all 16132)
# Title Authors PMID Year
1
Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. 61 54
15308523 2004
2
Animal models of inflammatory spinal and sacroiliac joint diseases. 61 54
12951872 2003
3
Effect of Interleukin-34 on Secretion of Angiogenesis Cytokines by Peripheral Blood Mononuclear Cells of Rheumatoid Arthritis. 61
31401905 2020
4
Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition. 61
31662318 2020
5
The effects of nanocurcumin on Treg cell responses and treatment of ankylosing spondylitis patients: A randomized, double-blind, placebo-controlled clinical trial. 61
31074089 2020
6
Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. 61
31734402 2020
7
Assessment of Ocular Surface in Patients With Ankylosing Spondylitis. 61
30817331 2020
8
Imputation-based analysis of MICA alleles in the susceptibility to ankylosing spondylitis. 61
30659049 2020
9
Response to: Imputation-based analysis of MICA alleles in the susceptibility to ankylosing spondylitis by Zhou et al. 61
30659051 2020
10
Venous involvement in inflammatory disorders. 61
31599799 2020
11
Isotretinoin-induced sacroiliitis in patients with hidradenitis suppurativa: a case-based review. 61
31455984 2019
12
Bacteria: back pain, leg pain and Modic sign-a surgical multicentre comparative study. 61
31576463 2019
13
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. 61
31813637 2019
14
TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis. 61
31652079 2019
15
Esophageal Perforation after Anterior Cervical Spine Surgery. 61
31352724 2019
16
The rs75862629 minor allele in the endoplasmic reticulum aminopeptidases intergenic region affects human leucocyte antigen B27 expression and protects from ankylosing spondylitis in Sardinia. 61
31209470 2019
17
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. 61
31732180 2019
18
Association study of copy number variants in CCL3L1, FCGR3A and FCGR3B genes with risk of ankylosing spondylitis in a West Algerian population. 61
31433132 2019
19
Do we need new trial designs in spondyloarthritis? 61
31779854 2019
20
[JAK inhibitors: Perspectives in internal medicine]. 61
31699450 2019
21
Novel Method for Removal of Broken Intramedullary Interlocking Nail with a Subtrochanteric Fracture: A Case Report. 61
31815808 2019
22
LncRNA TUG1 was upregulated in osteoporosis and regulates the proliferation and apoptosis of osteoclasts. 61
31815638 2019
23
Surgical Treatment of Ankylosing Spondylitis with Andersson Lesion. 61
31779768 2019
24
Usefulness of dynamic contrast-enhanced magnetic resonance images for distinguishing between pyogenic spondylitis and tuberculous spondylitis. 61
31286247 2019
25
[Analysis of influencing factors for pathogen culture result in patients with pyogenic spondylitis]. 61
31848501 2019
26
[Debridement and interbody fusion via posterior pedicle lateral approach for ankylosing spondylitis with thoracolumbar Andersson lesion]. 61
31823543 2019
27
Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review. 61
31847607 2019
28
Gender and chronic kidney disease in ankylosing spondylitis: a single-center retrospectively study. 61
31818273 2019
29
Metagenomic profiling of the pro-inflammatory gut microbiota in ankylosing spondylitis. 61
31806420 2019
30
miR-214 stimulated by IL-17A regulates bone loss in patients with ankylosing spondylitis. 61
31846044 2019
31
Relationship between sleep quality and physical activity level in patients with ankylosing spondylitis. 61
31810412 2019
32
Two-Level Osteotomy for the Corrective Surgery of Severe Kyphosis From Ankylosing Spondylitis: A Retrospective Series. 61
31725686 2019
33
miR-17-5p Regulates Heterotopic Ossification by Targeting ANKH in Ankylosing Spondylitis. 61
31726387 2019
34
HLA-B27-mediated activation of TNAP phosphatase promotes pathogenic syndesmophyte formation in ankylosing spondylitis. 61
31682238 2019
35
TIMP3 gene polymorphisms and relation to Ankylosing spondylitis susceptibility in Chinese Han population. 61
31397536 2019
36
Treg-promoted New Bone Formation Through Suppressing TH17 by Secreting Interleukin-10 in Ankylosing Spondylitis. 61
31348182 2019
37
Cauda Equina Syndrome in Ankylosing Spondylitis: Challenges in Diagnosis, Management, and Pathogenesis. 61
30936280 2019
38
[Hypophosphatemic osteomalacia caused by urinary mesenchymal tumor: A case report]. 61
31848524 2019
39
Usefulness of CHA2 DS2 -VASc score to predict mortality and hospitalization in patients with inflammatory arthritis. 61
31854508 2019
40
Prevalence of axial spondyloarthritis in Poland. 61
31802208 2019
41
Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO). 61
31791950 2019
42
Platelet indices in patients with chronic inflammatory arthritis: a systematic review and meta-analysis. 61
31852367 2019
43
Investigation of anti-DFS70 antibody in patients with systemic autoimmune rheumatic diseases. 61
31396837 2019
44
A cross talk between dysbiosis and gut-associated immune system governs the development of inflammatory arthropathies. 61
31208713 2019
45
Hepatosplenic T-Cell Lymphoma Arising in a Patient Treated With Tumor Necrosis Factor-α Inhibitors for Ankylosing Spondylitis. 61
31764502 2019
46
Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis. 61
31848735 2019
47
Ankylosing Spondylitis Complicated with Atlantoaxial Dislocation and Destruction of the Dens and Lateral Atlantoaxial Joint: A Case Report. 61
31833976 2019
48
Serum Uric Acid Shows Inverted "U" Type Correlation with Osteoporosis in Chinese Ankylosing Spondylitis Patients: A Retrospective Study. 61
31851643 2019
49
Effect of biologics in the level of cytokines in the synovial fluid of patients with ankylosing spondylitis. 61
31830775 2019
50
Validity and reliability of the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritis (axSpA) in Singapore. 61
31721427 2019

Variations for Spondylitis

Expression for Spondylitis

Search GEO for disease gene expression data for Spondylitis.

Pathways for Spondylitis

Pathways related to Spondylitis according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.48 TNFRSF1B TNF TAP2 TAP1 NOD2 MICA
2
Show member pathways
13.23 TNFRSF1B TNF LTA IL6 IL23R IL17A
3
Show member pathways
13.18 TNFRSF1B TNF NOD2 LTA IL6 IL23R
4
Show member pathways
12.76 TNF TAP2 TAP1 IL6 HLA-C HLA-B
5
Show member pathways
12.72 TNFRSF1B TNF TAP2 TAP1 MICA IL6
6 12.71 TNF TAP2 TAP1 LTA IL6 HLA-C
7
Show member pathways
12.55 TNF TAP2 TAP1 MICA LTA IL6
8
Show member pathways
12.53 TNF NOD2 IL6 IL23R IL17A
9 12.5 TNFRSF1B TNF TAP2 TAP1 IL1RN IL17A
10 12.31 TNF LTA IL6 HLA-C HLA-B
11
Show member pathways
12.29 TNFRSF1B TNF LTA IL6 CCR6
12
Show member pathways
12.21 TNF LTA IL6 IL17A HLA-C HLA-B
13 12.07 TAP2 TAP1 HLA-C HLA-B
14
Show member pathways
11.97 TNF LTA IL6 IL23R IL17A
15 11.89 TNFRSF1B TNF IL6 IL23R IL17A
16 11.85 TNFRSF1B TNF NOD2 LTA IL6
17 11.69 TNF IL6 IL1RN IL17A
18 11.56 TNF LTA IL23R IL17A CCR6
19 11.52 TNFRSF1B TNF LTA
20 11.49 TNFRSF1B TNF IL6 IL1RN
21
Show member pathways
11.48 TNFRSF1B TNF LTA
22 11.27 TNF IL6 IL17A
23 11 TNF IL6 CRP
24 10.5 TAP2 TAP1 HLA-C HLA-B ERAP2 ERAP1

GO Terms for Spondylitis

Cellular components related to Spondylitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.02 TNFRSF1B TNF SOST LTA IL6 IL1RN
2 cell surface GO:0009986 9.85 TNF NOD2 MICA HLA-C HLA-B CCR6
3 external side of plasma membrane GO:0009897 9.63 TNF MICA IL23R IL17A HLA-B CCR6
4 MHC class I protein complex GO:0042612 9.43 HLA-C HLA-B
5 MHC class I peptide loading complex GO:0042824 9.4 TAP2 TAP1
6 extracellular space GO:0005615 9.36 TNF SOST MICA LTA IL6 IL1RN
7 TAP complex GO:0042825 9.26 TAP2 TAP1
8 phagocytic vesicle membrane GO:0030670 9.26 TAP2 TAP1 HLA-C HLA-B

Biological processes related to Spondylitis according to GeneCards Suite gene sharing:

(show all 30)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.92 TAP2 TAP1 NOD2 IL23R HLA-C HLA-B
2 cellular response to lipopolysaccharide GO:0071222 9.88 TNFRSF1B TNF NOD2 IL6 IL1RN
3 cytokine-mediated signaling pathway GO:0019221 9.88 TNFRSF1B TNF IL6 IL23R IL1RN IL17A
4 defense response to Gram-positive bacterium GO:0050830 9.87 TNF LTA IL6 CRP
5 positive regulation of JNK cascade GO:0046330 9.82 TNF NOD2 IL1RN
6 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.8 TAP2 TAP1 HLA-C HLA-B
7 inflammatory response GO:0006954 9.8 TNFRSF1B TNF IL6 IL23R IL1RN IL17A
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.79 TNF IL6 IL23R
9 response to glucocorticoid GO:0051384 9.78 TNF IL6 IL1RN
10 positive regulation of interleukin-6 production GO:0032755 9.76 TNF NOD2 IL6 IL1RN
11 positive regulation of interferon-gamma production GO:0032729 9.75 TNF LTA IL23R
12 positive regulation of T cell mediated cytotoxicity GO:0001916 9.73 MICA IL23R HLA-B
13 humoral immune response GO:0006959 9.73 TNF LTA IL6 CCR6
14 positive regulation of osteoclast differentiation GO:0045672 9.7 TNF IL23R IL17A
15 positive regulation of glial cell proliferation GO:0060252 9.69 TNF LTA IL6
16 positive regulation of neuroinflammatory response GO:0150078 9.65 TNF IL6
17 immune response GO:0006955 9.65 TNFRSF1B TNF MICA LTA IL6 IL1RN
18 peptide transport GO:0015833 9.64 TAP2 TAP1
19 regulation of neuroinflammatory response GO:0150077 9.63 TNFRSF1B IL6
20 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.63 MICA HLA-B
21 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.62 MICA HLA-B
22 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.61 HLA-C HLA-B
23 vesicle fusion with endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane GO:1990668 9.6 TAP2 TAP1
24 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.59 IL6 IL1RN
25 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.58 TNF LTA
26 cytosol to ER transport GO:0046967 9.55 TAP2 TAP1
27 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.54 TNF LTA
28 negative regulation of lipid storage GO:0010888 9.54 TNF IL6 CRP
29 antigen processing and presentation of endogenous peptide antigen via MHC class I GO:0019885 9.46 TAP2 TAP1 ERAP2 ERAP1
30 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.1 TAP2 TAP1 HLA-C HLA-B ERAP2 ERAP1

Molecular functions related to Spondylitis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.36 TNFRSF1B TNF TAP2 TAP1 SOST NOD2
2 MHC protein binding GO:0042287 9.49 TAP2 TAP1
3 peptide transmembrane transporter activity GO:1904680 9.48 TAP2 TAP1
4 interleukin-6 receptor binding GO:0005138 9.46 IL6 ERAP1
5 MHC class Ib protein binding GO:0023029 9.43 TAP2 TAP1
6 TAP1 binding GO:0046978 9.37 TAP2 TAP1
7 peptide antigen binding GO:0042605 9.33 TAP1 HLA-C HLA-B
8 peptide-transporting ATPase activity GO:0015440 9.32 TAP2 TAP1
9 peptide antigen-transporting ATPase activity GO:0015433 9.26 TAP2 TAP1
10 cytokine activity GO:0005125 9.02 TNF LTA IL6 IL1RN IL17A
11 interleukin-1, type II receptor binding GO:0005151 8.96 IL1RN ERAP1

Sources for Spondylitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....